Dual GLP-1/GIP receptor agonists (DA) have been tested to perform better than single GLP-1 receptor agonists (exenatide, liraglutide, etc.)in PD mouse models and are considered promising as therapeutic agents for PD. This evidence concerns the gene GCG and Parkinson disease.